摘要
目的:探讨糖皮质激素在IgA肾病治疗中的价值及安全性分析。方法:运用Cochrane图书馆和PubMed等数据库检索糖皮质激素治疗IgA肾病的相关文献,对符合标准的文献进行质量评价,采用RevMan4.2软件进行Meta分析。结果:激素治疗组与对照组相比激素治疗组降低了血肌酐成倍增长或发展至终末期肾病的风险,同时不同蛋白尿程度、有无高血压、治疗前有无肾功能受损及不同的肾脏病理表现的患者激素治疗后尿蛋白水平均显著降低。但激素治疗组相比于对照组增加了不良反应事件的发生。结论:对伴有中到大量蛋白尿的患者,糖皮质激素治疗可降低蛋白尿、改善患者远期预后。同时糖皮质激素对药物治疗的安全性有影响但无统计学差异。
Objective： To investigate the effects of glucocorticoids on IgA nephropathy and its safe- ty. Methods： Literatures about treating IgA nephropathy with glucoeortieoid were retrived from Cochrane library and Pubmed database, those met the selection standards were analyzed by RevMan 4.2 for Meta a- nalysis. Results： Hormone treatment group declined risks of double increase of serum creatinine and the risk of occurrence of end-stage renal disease comparing with control group. For patients with different lev- els of proteinuria, with or without hypertension, with different severity of impaired kidney function or dif- ferent renal pathological manifestations, hormone treatment can decrease the urine protein levels. But the hormone treatment also increased the occurrence of adverse events comparing with control group. Oonclu- sion： For patients with medium to large amount of duce proteinuria and improve long-term prognosis. medication but the difference is not significant. proteinuria in patients, glucocorticoid therapy can re- And glucocorticoids have influence on the safety of medication but the difference is not significant.
出处
《海南医学院学报》
CAS
2013年第11期1527-1529,共3页
Journal of Hainan Medical University
基金
中国高校医学期刊临床专项资金项目(112210849)~~
